SCHEMBL18153286

SCHEMBL18153286

FC(F)(F)c1cc(Nc2ccccn2)nc(Cl)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
KCNH2 Q12809 1/20 0.47
KDM4E B2RXH2 2/20 0.47
CYP1A2 P05177 2/20 0.44
CTSC P53634 1/20 0.44
MEN1 O00255 1/20 0.42
MAPK10 P53779 1/20 0.42
GFER P55789 1/20 0.42
ALDH1A1 P00352 1/20 0.41
ABL1 P00519 1/20 0.40
PIM1 P11309 1/20 0.40
KDR P35968 1/20 0.40
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
CDK5 Q00535 1/20 0.39
DYRK1A Q13627 1/20 0.39
CDK5R1 Q15078 1/20 0.39
CYP2C9 P11712 1/20 0.39
BLM P54132 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4595845 0.80 KMT2A (0.48) KMT2AKDM4EMEN1MAPK10GFER
SCHEMBL4595367 0.77 KDR (0.47) KMT2AKCNH2KDM4ECYP1A2MEN1
SCHEMBL18162526 0.76 KMT2A (0.46) KMT2AKCNH2KDM4ECYP1A2ALDH1A1
SCHEMBL1258158 0.74 PDE4D (0.46) KMT2AKCNH2KDM4ECYP1A2MEN1
SCHEMBL4595519 0.73 KMT2A (0.42) KMT2AKDM4EMEN1MAPK10GFER
SCHEMBL23221500 0.73 CYP1A2 (0.57) KMT2AKDM4ECYP1A2MEN1ALDH1A1
SCHEMBL18153263 0.73 APP (0.50) KMT2AKCNH2KDM4ECYP1A2CTSC
SCHEMBL2822274 0.73 KMT2A (0.52) KMT2AKDM4EMEN1MAPK10GFER
SCHEMBL24350501 0.72 PIK3C3 (0.54) KMT2AMEN1ABL1KDRCDK5
Hydrochloric Acid SCHEMBL18153414 0.72 ADRB1 (0.53) KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283472-B1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS UNIV INDIANA RES & TECH CORP (US) 2021-04-14 EP disclosed
EP-3283472-B1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS UNIV INDIANA RES & TECH CORP (US) 2021-04-14 EP disclosed
US-10273228-B2 Hepatitis B viral assembly effectors INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-04-30 US disclosed
US-10273228-B2 Hepatitis B viral assembly effectors INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2019-04-30 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
EP-3283472-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS Indiana University Research&Technology Corporation (US) 2018-02-21 EP disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS HAVCR2, MAVS, HCCS KMT2A 4450/4885KCNH2 4825/4885KDM4E 3876/4885
US-10273228-B2 Hepatitis B viral assembly effectors HAVCR2, MAVS, HCCS KMT2A 4450/4885KCNH2 4825/4885KDM4E 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.